Dr. Lipinski is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
650 Peter Jefferson Pkwy
Ste 100
Charlottesville, VA 22911Phone+1 434-293-4072Fax+1 434-293-4265
Education & Training
- MedStar Health/Georgetown-Washington Hospital CenterFellowship, Interventional Cardiology, 2013 - 2015
- University of Virginia Medical CenterFellowship, Cardiovascular Disease, 2008 - 2013
- University of VirginiaPhD, Molecular Physiology and Biological Physics, 2008 - 2012
- University of Virginia Medical CenterResidency, Internal Medicine, 2006 - 2008
- Virginia Commonwealth University School of MedicineClass of 2006
- Stanford UniversityBS, Biological Sciences, 1996 - 2000
Certifications & Licensure
- VA State Medical License 2006 - 2026
- DC State Medical License 2013 - 2024
- American Board of Internal Medicine Cardiovascular Disease
- American Board of Internal Medicine Interventional Cardiology
Publications & Presentations
PubMed
- Editorial: Bivalirudin with post-procedural infusion: Should the Guidelines change to keep up with the data?Michael J Lipinski
Cardiovascular Revascularization Medicine. 2023-12-01 - 2 citationsComparison of Safety and Biological Efficacy of Anakinra (Kineret) Dispensed in Polycarbonate Plastic versus Borosilicate Glass Syringes: A Patient-Level Analysis of V...Azita H Talasaz, Robin Sculthorpe, Mary Pak, Michael Lipinski, Charlotte Roberts
The Journal of Pharmacology and Experimental Therapeutics. 2023-08-01 - 41 citationsInterleukin-1 blockade with Anakinra and heart failure following ST-segment elevation myocardial infarction: results from a pooled analysis of the VCUART clinical trials.Antonio Abbate, George F. Wohlford, Marco Giuseppe Del Buono, Juan Guido Chiabrando, Roshanak Markley
European Heart Journal. Cardiovascular Pharmacotherapy. 2021-10-07
Authored Content
- The PREVENT Trial: Vulnerable Plaque Is BackApril 2024
- FDA Cardiovascular Device News UpdateApril 2018
- FDA Cardiovascular Device News UpdateApril 2018
Press Mentions
- A Rapid Transformation for Covid’s Long HaulNovember 4th, 2020
- Important Interventional Trials from ESC Congress 2019October 7th, 2019
- Important Trial Results for Interventional Cardiology from ACC.19May 13th, 2019
- Join now to see all
Professional Memberships
- Member
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence: